HER-2 enriched subtype predicts for HER2 blockade benefit with lapatinib and trastuzumab
Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.
Researchers found wide variances in the cost of breast cancer chemotherapy, depending on the course of treatment selected.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
Patients undergoing treatment for breast cancer with trastuzumab-containing regimens need to be monitored for heart damage regardless of age.
Women with the HER2-enriched type of HER2-positive breast cancer had the highest rate of immune response to treatment with trastuzumab, with a significant increase after just 1 dose of the drug.
Research in mouse models has identified molecules that can bind to cancer cells and induce apoptosis.
Trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients, according to a large national study.
Researchers have found that subcutaneous trastuzumab has a similar safety profile and similar event-free survival rate with intravenous trastuzumab.
The addition of trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
Herceptin in addition to chemotherapy boosts survival, reduces risk of cancer recurrence
Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancerOctober 07, 2014
The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.
In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug trastuzumab is associated with prolonged survival but also increases the risk of developing heart problems
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
A new approach selectively permeabilizes the blood-brain barrier at sites of brain metastases, even those 200 times smaller than currently detectable in the clinic.
Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent of the molecular pathways that could be expected to be involved.
The monoclonal antibody trastuzumab (Herceptin) may be effective against HER2-negative breast cancers in addition to HER2-positive disease.
The protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative. The drug trastuzumab (Herceptin), which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|